Skip to main content

Equillium, Inc.

EQ
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001746466

No open-market purchases or sales by Equillium, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $133.0M in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding Equillium, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of EQ: Q3 2023 compared with Q4 2023
MeasureQ3 2023Of which not filed for Q4 2023Q4 2023Change
Holders25125+1
Shares9.12M4.45M9.48M+4.80M (+102.8%)
Value$6.75M$3.29M$6.85M+$3.39M (+98.0%)

1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (6)

Institutions that held Equillium, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to EQ in Q4 2023
InstitutionSharesValue% of portfolio
Decheng Capital LLC4,447,308$3.22M0.90%
Takeda Pharmaceutical Co Ltd1,824,977$1.31M0.40%
Commonwealth Equity Services, LLC100,000$72.0K0.00%
Jane Street Group, LLC12,040$8.71K0.00%
ADAR1 Capital Management, LLC6,500$4.70K0.00%
Bank of America Corp12$90.00%

Sold out (5)

Institutions that held Equillium, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.

Institutions that sold out of EQ in Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
Franklin Resources Inc895,000$662.3K
Bridgeway Capital Management, LLC125,500$92.9K
DCF Advisers, LLC69,871$51.7K
Two Sigma Securities, LLC36,287$26.9K
Simplex Trading, LLC2,073$1.00K

Not filed for Q4 2023 yet (1)

Institutions that held Equillium, Inc. at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding EQ in Q3 2023 that haven't filed for Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
Decheng Capital Management III (Cayman), LLC4,447,308$3.29M